Yaping Chen
Research Subjects
Yaping Chen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ali-Reza Shokouhi
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
1 shared publication- Jilong Wang
School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325000, China.
1 shared publication - Junjie Deng
Department of Orthopedics, The Second Affiliated Hospital and Yuying, Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
1 shared publication Luyao Bai
Joint Centre of Translational Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Medical University Wenzhou Zhejiang China
1 shared publicationLuyi Ye
Joint Centre of Translational Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Medical University Wenzhou Zhejiang China
1 shared publication- Nicolas Hans Voelcker
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
1 shared publication
Latest Publications
- Open Access
- 20 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (40) , e75406
Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy
Macrophage‐based immunotherapy holds great promise for solid tumors but is limited by impaired phagocytosis and unstable M1‐type polarization due to immunosuppressive tumor microenvironments. Here, we develop engineered macrophages by conjugating oncolytic adenovirus (OA)‐loaded zeolitic imidazolate framework‐8 (ZIF‐8) onto macrophage surfaces via bioorthogonal chemistry (ZIFOA‐M). This platform leverages localized viral delivery to selectively downregulate “don't eat me” signals (CD47 and CD24) on tumor cells, thereby restoring macrophage phagocytic capacity. Moreover, viral replication within tumors induces immunogenic cell death, releasing major damage‐associated molecular patterns (DAMPs) that sustain M1‐type polarization and promote durable antitumor immunity. ZIFOA‐M also enhances tumor antigen presentation, eliciting robust tumor‐specific T cell responses. Our strategy integrates phagocytosis restoration, microenvironment remodeling, and adaptive immune activation in a single, localized platform. ZIFOA‐M offers a complementary and translatable approach to overcome key barriers in macrophage‐based cancer immunotherapy.
- 20 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (40) , e75406
Open AccessEngineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy
Macrophage‐based immunotherapy holds great promise for solid tumors but is limited by impaired phagocytosis and unstable M1‐type polarization due to immunosuppressive tumor microenvironments. Here, we develop engineered macrophages by conjugating oncolytic adenovirus (OA)‐loaded zeolitic imidazolate framework‐8 (ZIF‐8) onto macrophage surfaces via bioorthogonal chemistry (ZIFOA‐M). This platform leverages localized viral delivery to selectively downregulate “don't eat me” signals (CD47 and CD24) on tumor cells, thereby restoring macrophage phagocytic capacity. Moreover, viral replication within tumors induces immunogenic cell death, releasing major damage‐associated molecular patterns (DAMPs) that sustain M1‐type polarization and promote durable antitumor immunity. ZIFOA‐M also enhances tumor antigen presentation, eliciting robust tumor‐specific T cell responses. Our strategy integrates phagocytosis restoration, microenvironment remodeling, and adaptive immune activation in a single, localized platform. ZIFOA‐M offers a complementary and translatable approach to overcome key barriers in macrophage‐based cancer immunotherapy.
- Open Access
- 31 May 2024
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 57 (12) , 1722-1735
Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering
ConspectusIn human cells, intracellular access and therapeutic cargo transport, including gene-editing tools (e.g., CRISPR-Cas9 and transposons), nucleic acids (e.g., DNA, mRNA, and siRNA), peptides, and proteins (e.g., enzymes and antibodies), are tightly constrained to ensure healthy cell function and behavior. This principle is exemplified in the delivery mechanisms of chimeric antigen receptor (CAR)-T cells for ex-vivo immunotherapy. In particular, the clinical success of CAR-T cells has established a new standard of care by curing previously incurable blood cancers. The approach involves the delivery, typically via the use of electroporation (EP) and lentivirus, of therapeutic CAR genes into a patient's own T cells, which are then engineered to express CARs that target and combat their blood cancer. But the key difficulty lies in genetically manipulating these cells without causing irreversible damage or loss of function─all the while minimizing complexities of manufacturing, safety concerns, and costs, and ensuring the efficacy of the final CAR-T cell product.Nanoinjection─the process of intracellular delivery using nanoneedles (NNs)─is an emerging physical delivery route that efficiently negotiates the plasma membrane of many cell types, including primary human T cells. It occurs with minimal perturbation, invasiveness, and toxicity, with high efficiency and throughput at high spatial and temporal resolutions. Nanoinjection promises greatly improved delivery of a broad range of therapeutic cargos with little or no damage to those cargos. A nanoinjection platform allows these cargos to function in the intracellular space as desired. The adaptability of nanoinjection platforms is now bringing major advantages in immunomodulation, mechanotransduction, sampling of cell states (nanobiopsy), controlled intracellular interrogation, and the primary focus of this account─intracellular delivery and its applications in ex vivo cell engineering.Mechanical nanoinjection typically exerts direct mechanical force on the cell membrane, offering a straightforward route to improve membrane perturbation by the NNs and subsequent transport of genetic cargo into targeted cell type (adherent or suspension cells). By contrast, electroactive nanoinjection is controlled by coupling NNs with an electric field─a new route for activating electroporation (EP) at the nanoscale─allowing a dramatic reduction of the applied voltage to a cell and so minimizing post-EP damage to cells and cargo, and overcoming many of the limitations of conventional bulk EP. Nanoinjection transcends mere technique; it is an approach to cell engineering ex vivo, offering the potential to endow cells with new, powerful features such as generating chimeric antigen receptor (CAR)-T cells for future CAR-T cell technologies.We first discuss the manufacturing of NN devices (Section 2), then delve into nanoinjection-mediated cell engineering (Section 3), nanoinjection mechanisms and interfacing methodologies (Section 4), and emerging applications in using nanoinjection to create functional CAR-T cells (Section 5).
- 31 May 2024
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 57 (12) , 1722-1735
Open AccessNanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering
ConspectusIn human cells, intracellular access and therapeutic cargo transport, including gene-editing tools (e.g., CRISPR-Cas9 and transposons), nucleic acids (e.g., DNA, mRNA, and siRNA), peptides, and proteins (e.g., enzymes and antibodies), are tightly constrained to ensure healthy cell function and behavior. This principle is exemplified in the delivery mechanisms of chimeric antigen receptor (CAR)-T cells for ex-vivo immunotherapy. In particular, the clinical success of CAR-T cells has established a new standard of care by curing previously incurable blood cancers. The approach involves the delivery, typically via the use of electroporation (EP) and lentivirus, of therapeutic CAR genes into a patient's own T cells, which are then engineered to express CARs that target and combat their blood cancer. But the key difficulty lies in genetically manipulating these cells without causing irreversible damage or loss of function─all the while minimizing complexities of manufacturing, safety concerns, and costs, and ensuring the efficacy of the final CAR-T cell product.Nanoinjection─the process of intracellular delivery using nanoneedles (NNs)─is an emerging physical delivery route that efficiently negotiates the plasma membrane of many cell types, including primary human T cells. It occurs with minimal perturbation, invasiveness, and toxicity, with high efficiency and throughput at high spatial and temporal resolutions. Nanoinjection promises greatly improved delivery of a broad range of therapeutic cargos with little or no damage to those cargos. A nanoinjection platform allows these cargos to function in the intracellular space as desired. The adaptability of nanoinjection platforms is now bringing major advantages in immunomodulation, mechanotransduction, sampling of cell states (nanobiopsy), controlled intracellular interrogation, and the primary focus of this account─intracellular delivery and its applications in ex vivo cell engineering.Mechanical nanoinjection typically exerts direct mechanical force on the cell membrane, offering a straightforward route to improve membrane perturbation by the NNs and subsequent transport of genetic cargo into targeted cell type (adherent or suspension cells). By contrast, electroactive nanoinjection is controlled by coupling NNs with an electric field─a new route for activating electroporation (EP) at the nanoscale─allowing a dramatic reduction of the applied voltage to a cell and so minimizing post-EP damage to cells and cargo, and overcoming many of the limitations of conventional bulk EP. Nanoinjection transcends mere technique; it is an approach to cell engineering ex vivo, offering the potential to endow cells with new, powerful features such as generating chimeric antigen receptor (CAR)-T cells for future CAR-T cell technologies.We first discuss the manufacturing of NN devices (Section 2), then delve into nanoinjection-mediated cell engineering (Section 3), nanoinjection mechanisms and interfacing methodologies (Section 4), and emerging applications in using nanoinjection to create functional CAR-T cells (Section 5).